Clinical Trial Update: Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sorafenib in combination with irinotecan for metastatic colorectal cancer with KRAS mutations has completed (status: completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle | Conditions: Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors | Phase 2 | Status: COMPLETED